Product Image

No Flush Niacin 500 mg

Natural Factors
4.7
★ ★ ★ ★ ★
(970 ratings)
Niacin 500 mg
Product Image
Score80
A clearly disclosed no-flush niacin complex that favors comfort and general B3 intake. It is not a direct substitute for nicotinic acid in lipid-focused use.
How scoring works
Quantity:90 Capsule(s) • (90 servings)
Goals:
Cardiovascular Support
Skin Health

Score 80

A clearly disclosed no-flush niacin complex that favors comfort and general B3 intake. It is not a direct substitute for nicotinic acid in lipid-focused use.
How scoring works
$16.07($0.17 per serving)
Vitacost
$ 16.07
iHerb
$ 16.07
Report prices

Analysis

The no-flush compound is named directly, and both its niacin and inositol components are disclosed. That makes the formula easier to assess than products that imply a bound form without stating it.

Inositol hexaniacinate generally produces less immediate flushing than nicotinic acid. The trade-off is weaker confidence for cardiovascular uses that depend specifically on nicotinic acid.

The capsule fits users prioritizing comfort and straightforward B3 supplementation. Skin support may be reasonable as part of general nutrition, but the large amount is not automatically more useful.

Who is it for
  • Adults sensitive to niacin flushing
  • People wanting a named no-flush form
  • Users seeking vitamin B3 with inositol
Best for
  • Tolerance-first niacin supplementation
  • General vitamin B3 intake
  • No-flush capsule routines

Pros

  • Clearly identifies inositol hexaniacinate
  • Discloses niacin and inositol components
  • Lower flushing potential

Cons

  • Less dependable for lipid-focused effects
  • Amount exceeds basic nutrient needs
  • More specialized than a standard B-complex

Warnings

  • Do not assume the no-flush form has the same lipid effects as nicotinic acid.
  • Large no-flush niacin servings may still cause stomach upset or affect liver markers with prolonged use.
  • Avoid stacking it with another vitamin B3 product without checking total intake.

Nutrient quality

82 Highest impact

Inositol hexanicotinate is a clearly named no-flush niacin derivative. The amount is meaningful for this less direct niacin form.

.

Ingredient transparency

81 Highest impact

All meaningful active amounts are clearly disclosed. The supplied data does not include a complete inactive ingredient list.

.

Customer satisfaction

68 High impact

The aggregate satisfaction measure is strong and supported by adequate volume. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.

Value for money

88 Highest impact

The price is reasonable for the formula quality and dose. Each serving provides good cost efficiency.

.
Report analysis

Goals

Cardiovascular Support
Impact
Moderate effect
C- Goal FitC Strength of SupportD- CoverageA Formula Quality
Niacin · 500 mg

Inositol hexaniacinate offers a flush-free niacin form, but it is less reliably aligned with lipid improvement than nicotinic acid. The cardiovascular evidence for this form is therefore limited despite its niacin label.

The substantial amount and exact chemical form are clearly disclosed. Inositol adds little separate value because it is part of the same compound rather than an independent cardiovascular pathway.

Study evidence
Niacin Supportive 136 studies
Skin Health
Impact
Moderate effect
D- Goal FitC- Strength of SupportF CoverageB Formula Quality

Inositol hexaniacinate is a no-flush niacin form, but it is not the niacinamide form most directly linked to skin-barrier support. Its release of active niacin is less predictable for this purpose.

The formula is clearly labeled and focused, yet it covers only one indirect pathway. Evidence for meaningful skin outcomes from oral inositol hexaniacinate is limited.

Study evidence
Niacin Supportive 61 studies

Ingredients

IngredientAmount per serving
Niacin (Inositol Hexaniacinate)
500 mg
Inositol (Inositol Hexaniacinate)
120 mg
Gluten Free Adults 18–50 Dairy Free Sugar Free
Report overview
B- Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyA+ Value

Inositol hexaniacinate offers a no-flush approach that can suit people seeking cardiovascular support without typical nicotinic acid flushing. The dose is substantial, though this form can require more material than pure nicotinic acid for comparable effects. Clear form naming and low serving cost make it a practical option within its specific trade-off.

Loading alternative details
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsCardiovascular Support forNiacin
  2. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledCardiovascular Support forNiacin
  3. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  4. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  5. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  6. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  7. Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xiang D; Zhang Q; Wang YT · Medicine · 2020
    Meta-analysis2,110 participants8 studies pooledCardiovascular Support forNiacin
  8. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  9. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2015
    Meta-analysis69,515 participants18 studies pooledCardiovascular Support forNiacin
  10. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  11. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  12. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  13. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
    Hakozaki T; Minwalla L; Zhuang J; Chhoa M; Matsubara A; Miyamoto K; Greatens A; Hillebrand GG; Bissett DL; Boissy RE · The British journal of dermatology · 2002
    Randomized trial138 participantsSkin Health forNiacin
  14. Niacinamide: A B vitamin that improves aging facial skin appearance.
    Bissett DL; Oblong JE; Berge CA · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2005
    Randomized trial50 participantsSkin Health forNiacin
  15. The clinical anti-aging effects of topical kinetin and niacinamide in Asians: a randomized, double-blind, placebo-controlled, split-face comparative trial.
    Chiu PC; Chan CC; Lin HM; Chiu HC · Journal of cosmetic dermatology · 2008
    Randomized trial52 participantsSkin Health forNiacin
  16. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
    Chen AC; Martin AJ; Choy B; Fernández-Peñas P; Dalziell RA; McKenzie CA; Scolyer RA; Dhillon HM; Vardy JL; Kricker A; St George G; Chinniah N; Halliday GM; Damian DL · The New England journal of medicine · 2015
    Randomized trial386 participantsSkin Health forNiacin
  17. Nicotinamide for Skin Cancer Chemoprevention.
    Breglio KF; Knox KM; Hwang J; Weiss R; Maas K; Zhang S; Yao L; Madden C; Xu Y; Hartman RI; Wheless L · JAMA dermatology · 2025
    Cohort study33,822 participantsSkin Health forNiacin